Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations
Open Access
- 31 March 2020
- journal article
- review article
- Published by MDPI AG in Applied Sciences
- Vol. 10 (7), 2376
- https://doi.org/10.3390/app10072376
Abstract
The increasing emergence of drug-resistant tuberculosis requires new effective and safe drug regimens. However, drug discovery and development are challenging, lengthy and costly. The framework of model-informed drug discovery and development (MID3) is proposed to be applied throughout the preclinical to clinical phases to provide an informative prediction of drug exposure and efficacy in humans in order to select novel anti-tuberculosis drug combinations. The MID3 includes pharmacokinetic-pharmacodynamic and quantitative systems pharmacology models, machine learning and artificial intelligence, which integrates all the available knowledge related to disease and the compounds. A translational in vitro-in vivo link throughout modeling and simulation is crucial to optimize the selection of regimens with the highest probability of receiving approval from regulatory authorities. In vitro-in vivo correlation (IVIVC) and physiologically-based pharmacokinetic modeling provide powerful tools to predict pharmacokinetic drug-drug interactions based on preclinical information. Mechanistic or semi-mechanistic pharmacokinetic-pharmacodynamic models have been successfully applied to predict the clinical exposure-response profile for anti-tuberculosis drugs using preclinical data. Potential pharmacodynamic drug-drug interactions can be predicted from in vitro data through IVIVC and pharmacokinetic-pharmacodynamic modeling accounting for translational factors. It is essential for academic and industrial drug developers to collaborate across disciplines to realize the huge potential of MID3.This publication has 134 references indexed in Scilit:
- Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro DataPLOS ONE, 2013
- Table_of_ContentsJournal of Deaf Studies and Deaf Education, 2013
- Quantifying the chemical beauty of drugsNature Chemistry, 2012
- Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary LesionsAntimicrobial Agents and Chemotherapy, 2012
- Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose OptimizationAntimicrobial Agents and Chemotherapy, 2011
- High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in Tuberculosis-Infected Rabbit Lungs and Granulomatous LesionsAnalytical Chemistry, 2011
- A High-Throughput Screen for Tuberculosis ProgressionPLOS ONE, 2011
- The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the ClinicThe AAPS Journal, 2011
- A Novel Strategy for Physiologically Based Predictions of Human PharmacokineticsClinical Pharmacokinetics, 2006
- Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug DevelopmentDrug Safety, 2001